CD-001 / CD Biopharma - LARVOL DELTA

Preclinical development of CD-001, a novel fusion protein combining PD-1 blockade with IL-21 for solid tumors (AACR 2025) - "CD-001 exhibits a well-characterized safety profile and potent antitumor activity in preclinical models, supporting its future development as a therapeutic candidate for advanced solid tumors. The dual mechanism of CD-001, combining PD-1 inhibition with targeted IL-21 delivery, represents a novel therapeutic strategy to enhance T cell-mediated immunity in cancer patients."

IO biomarker • Preclinical • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Oncology • Solid Tumor • CD8 • IL21

CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001 (PRNewswire) - "CD (Suzhou) Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application of CD-001, entering a Phase I first-in-human trial....'We are excited to move forward with patient enrollment and expect initial clinical data in the upcoming months.'"

IND • New P1 trial • Oncology